Mothers, take note. If you really want to curb your teens’ chances of using alcohol, help them develop a self-view that doesn’t include drinking. According to a new Iowa State University study, the power of positive thinking by moms may limit their children’s alcohol use. But beware. The opposite is also true.

continue reading.....

Enanta Pharmaceuticals, a leader in the development of small molecule anti-infective drugs, announced today the initiation of a Phase 1 study on investigational oral antibiotic EDP-322, a first-in-class MRSA-active Bicyclolide, a novel macrolide-related drug class with a distinct resistance profile.

continue reading.....

Sanofi pasteur, the vaccines division of the sanofi-aventis Group, announced that it is sponsoring a Phase II clinical study exploring a multi-pronged treatment approach to high risk and advanced-stage melanoma — an often fatal form of cancer for which there are limited treatment options. Patients are being enrolled in the United States and Canada.

continue reading.....

BioSpecifics Technologies Corp. (OTC Bulletin Board: BSTC), a biopharmaceutical company developing first in class collagenase based products, announced the initiation of a U.S. Phase IIb clinical trial in Peyronie’s disease for its injectable collagenase, XIAFLEX (TM), by its partner Auxlium Pharmaceuticals, Inc.

continue reading.....

The American Pharmacists Association (APhA) applauds Rep. Marion Berry for introducing a House resolution (H.Res.1437) that would designate October as American Pharmacists Month (APhM).

continue reading.....

Mymetics Corporation (OTCBB: MYMX), a vaccine development company, is pleased to announce their preliminary SHIV challenge results on non-human primates previously immunized with the Company’s mucosal HIV-AIDS vaccine designed for triggering mucosal protection. The results significantly exceed the Industry standard of 60% to 70% effectiveness to be considered as a promising vaccine as well as of Mymetics’ expectation which was considerable above this level.

continue reading.....

Novavax, Inc. (Nasdaq: NVAX) announced vaccination of healthy volunteers in a Phase II clinical trial of its virus-like particle (VLP) based seasonal influenza vaccine. The Phase IIa randomized, placebo controlled clinical trial will evaluate the safety and immunogenicity of different doses of its seasonal influenza VLP vaccine.

continue reading.....

Repligen Corporation (Nasdaq: RGEN) reported publication of a preclinical study demonstrating that a novel histone deacetylase (HDAC) inhibitor improved disease symptoms in a transgenic animal model of Huntington’s disease. The study, led by scientists at The Scripps Research Institute, demonstrated that oral administration of the drug candidate to the mice after the onset of symptoms slowed the progression of disease.

continue reading.....

Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, announced that it has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for ENB-0040, its enzyme replacement therapy (ERT) for hypophosphatasia, a rare, life-threatening genetic bone disease. In August 2008, Enobia dosed the first patient in a Phase I clinical trial of ENB-0040.

continue reading.....

Data presented at the World Congress on Treatment and Research in Multiple Sclerosis (WCTRIMS) demonstrated that early initiation of Betaseron(R) (interferon beta-1b) treatment had a greater impact on long-term outcomes, when compared to delayed treatment.

continue reading.....